Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTX Nkarta

Pre-Mkt 08-18 08:04:29 EDT

2.43

+0.10

+4.29%

盘前2.40

-0.03-1.23%

07:07 EDT

High2.45	Low2.33	Vol394.42K
Open2.34	D1 Closing2.33	Amplitude5.15%
Mkt Cap173.86M	Tradable Cap146.88M	Total Shares71.55M
T/O948.98K	T/O Rate0.65%	Tradable Shares60.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTX","market":"US","secType":"STK","nameCN":"Nkarta","latestPrice":2.43,"timestamp":1786996800000,"preClose":2.33,"halted":0,"volume":394422,"hourTrading":{"tag":"盘前","latestPrice":2.4,"preClose":2.43,"latestTime":"07:07 EDT","volume":52,"amount":129.31000160000002,"timestamp":1787051274752,"change":-0.03,"changeRate":-0.012346,"amplitude":0.037037},"delay":0,"changeRate":0.04291845493562235,"floatShares":60443200,"shares":71545358,"eps":-1.587334,"marketStatus":"Pre-Mkt","change":0.1,"latestTime":"08-18 08:04:29 EDT","open":2.34,"high":2.45,"low":2.33,"amount":948976.0977395999,"amplitude":0.051502,"askPrice":2.41,"askSize":499,"bidPrice":2.36,"bidSize":1647,"shortable":3,"etf":0,"ttmEps":-1.587334,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787059800000},"marketStatusCode":1,"adr":0,"listingDate":1594353600000,"exchange":"NASDAQ","adjPreClose":2.43,"preHourTrading":{"tag":"盘前","latestPrice":2.4,"preClose":2.43,"latestTime":"07:07 EDT","volume":52,"amount":129.31000160000002,"timestamp":1787051274752,"change":-0.03,"changeRate":-0.012346,"amplitude":0.037037},"postHourTrading":{"tag":"盘后","latestPrice":2.39,"preClose":2.43,"latestTime":"19:34 EDT","volume":2689,"amount":6498.87,"timestamp":1787009643144,"change":-0.04,"changeRate":-0.016461,"amplitude":0.016461},"volumeRatio":0.803592166489947,"impliedVol":1.501,"impliedVolPercentile":0.94},"requestUrl":"/m/hq/s/NKTX/wiki","defaultTab":"wiki","newsList":[{"id":"2660399544","title":"Mizuho Securities Sticks to Their Buy Rating for Nkarta (NKTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660399544","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660399544?lang=en_us&edition=fundamental","pubTime":"2026-08-18 00:15","pubTimestamp":1786983336,"startTime":"0","endTime":"0","summary":"In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Nkarta, with a price target of $12.00. Syed covers the Hea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-nkarta-nktx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659673481","title":"Equillium Q2 Post Narrower Net Loss than Expected; Starts R&D Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2659673481","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659673481?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:20","pubTimestamp":1786652418,"startTime":"0","endTime":"0","summary":"Equillium Q2 post narrower net loss than expected; starts R&D initiativesOverviewUS biotech innovator's Q2 net loss narrowed and beat analyst expectationsQ2 loss per share beat analyst expectationsCom","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A159:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BK4007","NKTX","FATE","BK4568","EQ","ARTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162295","title":"NuCana Q2 Loss Narrows as Clinical Milestones Remain on Track","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162295","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162295?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:11","pubTimestamp":1786651881,"startTime":"0","endTime":"0","summary":"NuCana Q2 loss narrows as clinical milestones remain on trackOverviewUK cancer drug developer's Q2 net loss narrowed to 3.1 mln from 24.1 mln yr/yrCompany ended Q2 with 19.5 mln in cash, expects runwa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A141:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","IMNM","PYXS","BK4563","BK4139","NCNA","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162459","title":"Assembly Biosciences Q2 Net Loss Narrows as Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162459","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162459?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:09","pubTimestamp":1786651778,"startTime":"0","endTime":"0","summary":"Assembly Biosciences Q2 net loss narrows as revenue risesOverviewUS biotech firm's Q2 revenue from Gilead collaboration rose yr/yr, net loss narrowedLower net loss driven by higher revenue, reduced R&","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A13Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","LU1571399168.USD","SG9999015978.USD","IE00B3T34201.USD","LU2112291526.USD","BK4568","LU1674673691.USD","LU0114720955.EUR","BIB","LU1066053197.SGD","IBBQ","LU1934455194.USD","BBH","LU2087621335.USD","LU2468319806.SGD","NKTX","LU0882574055.USD","SG9999015986.USD","LU0122379950.USD","BK4505","BK4566","LU1839511570.USD","ARTL","LU0320765992.SGD","LU1061106388.HKD","ASMB","BK4007","LU1585245621.USD","LU0965509283.SGD","LU0109394709.USD","LU1934455277.USD","IE00B19Z3581.USD","LU1023059063.AUD","LU0965508806.USD","IE00BZ1G4Q59.USD","MEDI","LU0289739699.SGD","LU0889565916.HKD","BK4578","TBXU","LU1674673428.USD","AVIR","BK4588","IBB","BMED","BK4139","LU1057294990.SGD","LU0965509010.AUD","TMED","GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659971152","title":"Ovid Therapeutics Q2 Revenue Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659971152","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659971152?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:44","pubTimestamp":1786625080,"startTime":"0","endTime":"0","summary":"Ovid Therapeutics Q2 revenue beats estimatesOverviewUS biopharma firm's Q2 revenue beat analyst expectationsCompany posted Q2 net loss as operating expenses rose on clinical study activityOvid secured","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0LF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","PRLD","BK4505","BK4139","OVID","CABA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658143972","title":"Century Therapeutics Q2 Net Loss Misses Estimates on Lease Termination Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658143972","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658143972?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:09","pubTimestamp":1786536564,"startTime":"0","endTime":"0","summary":"Century Therapeutics Q2 net loss misses estimates on lease termination lossOverviewU.S. cell therapy developer's Q2 net loss widened yr/yr, missing analyst expectationsQ2 operating income missed analy","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490G8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SANA","NKTX","BK4539","PROK","IPSC","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658436649","title":"Pliant Therapeutics Q2 Net Loss Narrows on Operating Expenses Decline, Reduced Headcount","url":"https://stock-news.laohu8.com/highlight/detail?id=2658436649","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658436649?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:19","pubTimestamp":1786479585,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics Q2 net loss narrows on operating expenses decline, reduced headcountOverviewUS biopharmaceutical firm's Q2 net loss narrowed from prior yearQ2 operating expenses fell sharply after","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480ZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","PLRX","BK4139","BK4505","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658191549","title":"Vor Biopharma Posts Wider-than-Expected Q2 Loss on Increased G&A Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658191549","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658191549?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:42","pubTimestamp":1786455769,"startTime":"0","endTime":"0","summary":"Vor Biopharma posts wider-than-expected Q2 loss on increased G&A costsOverviewUS biotech firm's Q2 net loss widened, missing analyst expectationsR&D expenses dropped sharply yr/yr due to prior licensi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480KQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACHV","MREO","NKTX","BK4139","VOR","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658975569","title":"Neurogene Q2 Adjusted Loss Per Share Misses Estimates on Employee Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658975569","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658975569?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:39","pubTimestamp":1786448351,"startTime":"0","endTime":"0","summary":"Neurogene Q2 adjusted loss per share misses estimates on employee costsOverviewUS biotech for rare neurological diseases reported Q2 adjusted loss per share missed analyst expectationsNet loss and ope","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480EZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","BK4139","GANX","BK4505","NGNE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658299160","title":"Shattuck Labs Q2 Net Loss Widens as R&D Spending Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2658299160","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658299160?lang=en_us&edition=fundamental","pubTime":"2026-08-11 18:25","pubTimestamp":1786443943,"startTime":"0","endTime":"0","summary":"Shattuck Labs Q2 net loss widens as R&D spending risesOverviewBiotechnology firm's Q2 net loss widened as R&D expenses increased and revenue remained nilCompany ended Q2 with $208.3 mln in cash and in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480B9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","STTK","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658999787","title":"Nkarta, Inc. : H.c. Wainwright Cuts Target Price to $14 from $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2658999787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658999787?lang=en_us&edition=fundamental","pubTime":"2026-08-11 18:07","pubTimestamp":1786442858,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nAZN4TD8F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658674229","title":"Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658674229","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658674229?lang=en_us&edition=fundamental","pubTime":"2026-08-11 14:50","pubTimestamp":1786431007,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT). N...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nkarta-nktx-and-rocket-pharmaceuticals-rckt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nkarta-nktx-and-rocket-pharmaceuticals-rckt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","RCKT","LU0029874061.USD","LABU","NKTX","BK4137","BK4588","XLV","XBI","BK4505","HCSG","BK4581","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952000","title":"Nkarta, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952000","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952000?lang=en_us&edition=fundamental","pubTime":"2026-08-11 06:01","pubTimestamp":1786399298,"startTime":"0","endTime":"0","summary":"Nkarta, Inc. reports results for the quarter ended June 30 - Earnings SummaryNkarta, Inc.NKTX.OQreported a quarterly adjusted loss of 54 cents per share for the quarter ended June 30, lower than the s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N44725Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","NKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658212954","title":"Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658212954","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658212954?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:04","pubTimestamp":1786395889,"startTime":"0","endTime":"0","summary":"Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.38) by 42.11 percent. This is a 74.19 percent decrease over losses of $(0.31) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61095667/nkarta-q2-eps-0-54-misses-0-38-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nkarta Q2 EPS $(0.54) Misses $(0.38) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951674","title":"Biotech Firm Nkarta Posts Q2 Net Loss; Cash Runway into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951674","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951674?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:32","pubTimestamp":1786393955,"startTime":"0","endTime":"0","summary":"Biotech firm Nkarta posts Q2 net loss; cash runway into 2029OverviewUS biotech firm reported Q2 net loss of $40.4 mln, or $0.54 per shareCompany ended Q2 with $243.2 mln in cash and investments, expec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470Y8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","NKTX","PROK","OLMA","BK4139","MGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951617","title":"Nkarta Q2 FY26 Net Loss Widens to $40.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951617","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951617?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:31","pubTimestamp":1786393874,"startTime":"0","endTime":"0","summary":"Nkarta Q2 FY26 net loss widens to $40.4 millionNkarta posted a net loss of $40.4 million, or $0.54 per share, for Q2 2026.R&D expense totaled $29 million, while G&A expense was $14.1 million.Cash, cas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL9yXbXm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","NKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658518009","title":"Nkarta Q2 EPS USD -0.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2658518009","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658518009?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:25","pubTimestamp":1786393516,"startTime":"0","endTime":"0","summary":"BRIEF-Nkarta Q2 EPS USD -0.54Aug 10 (Reuters) - Nkarta Q2 basic EPS USD -0.54.Q2 net income USD -40.368 millionQ2 cash & investments USD 243.2 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nPLXP3319D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NKTX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951893","title":"Nkarta Q2 Cash & Investments USD 243.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951893?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:24","pubTimestamp":1786393457,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nPLXP3319D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NKTX","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658549439","title":"Nkarta, - Expects Cash to Fund Operations into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2658549439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658549439?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:24","pubTimestamp":1786393457,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nPLXP3319D:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTX","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951869","title":"Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951869?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:24","pubTimestamp":1786393456,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA7BSHG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTX","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nkartatx.com","stockEarnings":[{"period":"1week","weight":-0.0122},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0933},{"period":"6month","weight":0.0897},{"period":"1year","weight":0.0429},{"period":"ytd","weight":0.3135}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0395},{"period":"3month","weight":0.0531},{"period":"6month","weight":0.1259},{"period":"1year","weight":0.2008},{"period":"ytd","weight":0.1331}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.051655},{"month":2,"riseRate":0.5,"avgChangeRate":0.038672},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.082697},{"month":4,"riseRate":0.666667,"avgChangeRate":0.177626},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.08485},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.112595},{"month":7,"riseRate":0.833333,"avgChangeRate":0.046365},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.034737},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.061634},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.060284},{"month":11,"riseRate":0.5,"avgChangeRate":-0.004483},{"month":12,"riseRate":0.333333,"avgChangeRate":0.310979}],"exchange":"NASDAQ","name":"Nkarta","nameEN":"Nkarta"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nkarta(NKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nkarta,NKTX,Nkarta股票,Nkarta股票老虎,Nkarta股票老虎国际,Nkarta行情,Nkarta股票行情,Nkarta股价,Nkarta股市,Nkarta股票价格,Nkarta股票交易,Nkarta股票购买,Nkarta股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nkarta(NKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}